Bioasis Technologies Inc. V.BTI

Hunter Syndrome

[prophetoffactz]

With BTI designating Hunter Syndrome as its lead xB3 candidate for clinical trials with expectation of initiation of human trials just over one year from now that could speak to how the relationship with Chiesi is progressing. With Hunter Syndrome as its lead BTI is going head-to-head against Denali which already has Hunter Syndrome in human clinical trials. BTI also has Gaucher's Disease in development with Oxyrane which is the most common Lysosomal Storage Disorder. From Hunter Syndrome, to Gaucher's Disease, to Chiesi Lysosomal Storage Disorders are a strategic focus and BTI wants to go head-to-head vs. Denali.

[KayakerBC]

With BTI designating Hunter Syndrome as its lead xB3 candidate for clinical trials with expectation of initiation of human trials just over one year from now that could speak to how the relationship with Chiesi is progressing. With Hunter Syndrome as its lead BTI is going head-to-head against Denali..... Hey POF.  Great to see you're back to pumping BTI.   What kind of stock

[prophetoffactz]

Given the strategic importance of Lysosomal Storage Disorders to Chiesi and BTI's now enhanced focus on Lysosomal Storage Disorders, willingness to go head-to-head with Denali, complementary assets to Chiesi's, and existing agreement with Chiesi these two companies may be destined for a broader agreement. Chiesi is also strategically focused on rare diseases.